|
US3910907A
(en)
|
1973-07-09 |
1975-10-07 |
Icn Pharmaceuticals |
Pyrazolo(1,5-a)-1,3,5-triazines
|
|
US5356897A
(en)
*
|
1991-09-09 |
1994-10-18 |
Fujisawa Pharmaceutical Co., Ltd. |
3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
|
|
JPH11193281A
(ja)
|
1997-10-27 |
1999-07-21 |
Takeda Chem Ind Ltd |
アデノシンａ３受容体拮抗剤およびチアゾール化合物
|
|
HK1044282A1
(zh)
|
1998-12-18 |
2002-10-18 |
Bristol-Myers Squibb Pharma Company |
作为趋化因子受体活性调节剂的n-脲基烷基-哌啶化合物
|
|
AU2482100A
(en)
|
1998-12-18 |
2000-07-03 |
Du Pont Pharmaceuticals Company |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
|
AU3126700A
(en)
|
1998-12-18 |
2000-07-03 |
Du Pont Pharmaceuticals Company |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
|
CA2347909A1
(en)
|
1998-12-18 |
2000-06-22 |
Joseph B. Santella, Iii |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
|
AU2057200A
(en)
|
1998-12-18 |
2000-07-03 |
Du Pont Pharmaceuticals Company |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
|
US6605623B1
(en)
|
1998-12-18 |
2003-08-12 |
Bristol-Myers Squibb Pharma Co. |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
|
US6525069B1
(en)
|
1998-12-18 |
2003-02-25 |
Bristol-Myers Squibb Pharma Co. |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
|
JP2000302680A
(ja)
|
1999-04-23 |
2000-10-31 |
Takeda Chem Ind Ltd |
脳保護剤
|
|
EP1205478A4
(en)
|
1999-08-06 |
2004-06-30 |
Takeda Chemical Industries Ltd |
P38MAP KINASE INHIBITORS
|
|
CA2404384A1
(en)
|
2000-03-30 |
2001-10-11 |
Takeda Chemical Industries, Ltd. |
Substituted 1,3-thiazole compounds, their production and use
|
|
EP1294690A2
(en)
|
2000-06-21 |
2003-03-26 |
Bristol-Myers Squibb Pharma Company |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
|
AU2001271357A1
(en)
|
2000-06-21 |
2002-01-02 |
Dupont Pharmaceuticals Company |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
|
WO2002051442A1
(en)
|
2000-12-26 |
2002-07-04 |
Takeda Chemical Industries, Ltd. |
Concomitant drugs
|
|
WO2002062792A1
(en)
|
2001-02-02 |
2002-08-15 |
Takeda Chemical Industries, Ltd. |
Jnk inhibitor
|
|
PT1368355E
(pt)
|
2001-03-14 |
2006-09-29 |
Gruenenthal Gmbh |
Pirazolopirimidinas e tiazolopirimidinas substituidas, como analgesicos
|
|
CA2442428A1
(en)
|
2001-03-28 |
2002-10-10 |
Mark D. Wittman |
Novel tyrosine kinase inhibitors
|
|
US7081454B2
(en)
|
2001-03-28 |
2006-07-25 |
Bristol-Myers Squibb Co. |
Tyrosine kinase inhibitors
|
|
EP1402900A1
(en)
|
2001-06-11 |
2004-03-31 |
Takeda Chemical Industries, Ltd. |
Medicinal compositions
|
|
JP2005510508A
(ja)
|
2001-11-08 |
2005-04-21 |
藤沢薬品工業株式会社 |
アデノシンアンタゴニストとしてのチアゾールピリダジノン類
|
|
CA2483306A1
(en)
*
|
2002-04-23 |
2003-11-06 |
Shionogi & Co., Ltd. |
Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
|
|
US7312215B2
(en)
|
2003-07-29 |
2007-12-25 |
Bristol-Myers Squibb Company |
Benzimidazole C-2 heterocycles as kinase inhibitors
|
|
TWI349550B
(en)
|
2003-12-26 |
2011-10-01 |
|
A thiazole derivative and adenosine a2a receptor antagonist containing the same
|
|
CA2551867C
(en)
|
2003-12-31 |
2010-08-17 |
Schering-Plough Ltd. |
Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives
|
|
GB0401336D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
|
JPWO2006070943A1
(ja)
|
2004-12-28 |
2008-06-12 |
武田薬品工業株式会社 |
縮合イミダゾール化合物およびその用途
|
|
US8178533B2
(en)
*
|
2005-06-01 |
2012-05-15 |
Ucb Pharma, S.A. |
2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
|
|
EA201000046A1
(ru)
*
|
2007-06-21 |
2011-02-28 |
Кара Терапеутикс, Инк. |
Замещенные имидазогетероциклы
|
|
WO2009027733A1
(en)
|
2007-08-24 |
2009-03-05 |
Astrazeneca Ab |
(2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents
|
|
US7868001B2
(en)
|
2007-11-02 |
2011-01-11 |
Hutchison Medipharma Enterprises Limited |
Cytokine inhibitors
|
|
US20110046127A1
(en)
|
2007-11-08 |
2011-02-24 |
Paolo Pevarello |
Imidazopyridazines for Use as Protein Kinase Inhibitors
|
|
US20100029657A1
(en)
|
2008-02-29 |
2010-02-04 |
Wyeth |
Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
|
|
EP2103614A1
(en)
|
2008-03-18 |
2009-09-23 |
Santhera Pharmaceuticals (Schweiz) AG |
Substituted imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators
|
|
WO2010063487A1
(en)
|
2008-12-05 |
2010-06-10 |
Merz Pharma Gmbh & Co. Kgaa |
Pyrazolopyrimidines, a process for their preparation and their use as medicine
|
|
EP2210891A1
(en)
|
2009-01-26 |
2010-07-28 |
Domain Therapeutics |
New adenosine receptor ligands and uses thereof
|
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
EP2402344A1
(en)
*
|
2010-06-29 |
2012-01-04 |
Basf Se |
Pyrazole fused bicyclic compounds
|
|
EP2402337A1
(en)
*
|
2010-06-29 |
2012-01-04 |
Basf Se |
Pyrazolopyridine compounds
|
|
EP2402343A1
(en)
*
|
2010-06-29 |
2012-01-04 |
Basf Se |
Pyrazole-fused bicyclic compounds
|
|
EP2402345A1
(en)
*
|
2010-06-29 |
2012-01-04 |
Basf Se |
Pyrazole fused bicyclic compounds
|
|
TWI617559B
(zh)
|
2010-12-22 |
2018-03-11 |
江蘇恆瑞醫藥股份有限公司 |
２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
|
|
WO2012100342A1
(en)
*
|
2011-01-27 |
2012-08-02 |
Université de Montréal |
Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
|
|
US9199979B2
(en)
|
2011-02-24 |
2015-12-01 |
Nerviano Medical Sciences S.R.L. |
Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
|
|
UA114490C2
(uk)
|
2011-10-06 |
2017-06-26 |
Байєр Інтеллектуал Проперті Гмбх |
Гетероциклілпіри(mі)динілпіразоли як фунгіциди
|
|
AR088082A1
(es)
|
2011-10-13 |
2014-05-07 |
Lilly Co Eli |
Moduladores selectivos del receptor androgeno
|
|
CN104418821A
(zh)
|
2013-08-22 |
2015-03-18 |
四川大学华西医院 |
2,4位取代的5-(3,4,5-三甲氧基苯基)噻唑衍生物及其制备方法和用途
|
|
ES2728932T3
(es)
*
|
2014-01-09 |
2019-10-29 |
Intra Cellular Therapies Inc |
Compuestos orgánicos
|
|
EP3227286B1
(de)
*
|
2014-12-02 |
2018-12-26 |
Bayer Pharma Aktiengesellschaft |
Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung
|
|
CN107427521B
(zh)
|
2015-03-27 |
2021-08-03 |
达纳-法伯癌症研究所股份有限公司 |
细胞周期蛋白依赖性激酶的抑制剂
|
|
PT3370768T
(pt)
|
2015-11-03 |
2022-04-21 |
Janssen Biotech Inc |
Anticorpos que se ligam especificamente ao pd-1 e seus usos
|
|
KR102706837B1
(ko)
|
2016-04-15 |
2024-09-19 |
캔써 리서치 테크놀로지 리미티드 |
Ret 키나아제 억제제로서의 헤테로사이클릭 화합물
|
|
US11608334B2
(en)
*
|
2017-02-08 |
2023-03-21 |
The National Institutes of Pharmaceutical R&D Co., Ltd. |
Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof
|
|
US10973820B2
(en)
|
2017-12-13 |
2021-04-13 |
Facio Intellectual Property B.V. |
Compounds for treatment of diseases related to DUX4 expression
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
CN117304191A
(zh)
|
2018-07-05 |
2023-12-29 |
因赛特公司 |
作为a2a/a2b抑制剂的稠合吡嗪衍生物
|
|
TWI817018B
(zh)
|
2019-06-28 |
2023-10-01 |
美商艾瑞生藥股份有限公司 |
用於治療ｂｒａｆ相關的疾病和失調症之化合物
|
|
EP4058461A1
(en)
|
2019-11-11 |
2022-09-21 |
Incyte Corporation |
Salts and crystalline forms of a pd-1/pd-l1 inhibitor
|
|
AU2021228284A1
(en)
|
2020-02-28 |
2022-09-29 |
Remix Therapeutics Inc. |
Compounds and methods for modulating splicing
|
|
MX2022012677A
(es)
|
2020-04-08 |
2023-01-11 |
Remix Therapeutics Inc |
Compuestos y metodos para modular el empalme.
|
|
CA3174353A1
(en)
|
2020-04-08 |
2021-10-14 |
Dominic Reynolds |
Compounds and methods for modulating splicing
|
|
TWI782504B
(zh)
|
2020-05-08 |
2022-11-01 |
美商美國禮來大藥廠 |
(三氟甲基)嘧啶-2-胺化合物
|
|
GB202011996D0
(en)
|
2020-07-31 |
2020-09-16 |
Adorx Therapeutics Ltd |
Antagonist compounds
|
|
GB202019622D0
(en)
|
2020-12-11 |
2021-01-27 |
Adorx Therapeutics Ltd |
Antagonist compounds
|
|
MX2023006728A
(es)
|
2020-12-16 |
2023-06-19 |
New Frontier Labs Llc |
Esteres de acido dicarboxilico para inducir un efecto analgesico.
|
|
PE20232040A1
(es)
|
2020-12-16 |
2023-12-21 |
New Frontier Labs Llc |
Esteres de acidos dicarboxilicos para el tratamiento de enfermedades y padecimientos asociados con la toxina fosfolipasa d
|
|
LT4263545T
(lt)
|
2020-12-16 |
2026-07-27 |
Amgen Inc. |
Prmt5 inhibitoriai
|